Regulatory Readiness Regulatory clearance is targeted for Galileo 4π within the next year, signaling near-term regulatory readiness and a window for early adopters. Engage prospective hospitals and radiotherapy centers with pilots and clinical workflow co creation to align on procurement timelines.

Early Pilot As a UCLA spinoff with Series A funding, Celestial is positioned to collaborate with leading academic and high-volume centers for pilot programs. Tailor outreach to oncology departments and radiotherapy centers to validate ROI, patient throughput, and integration with existing planning and IT systems.

Partnership Strategy Disruptive robotic radiotherapy invites collaboration with large hospital networks and strategic medtech partners for co development, manufacturing scale up, and distribution. Explore joint ventures, OEM agreements, or clinical trial collaborations to accelerate adoption.

Competitive Advantage Galileo 4π claims optimized beam paths across a wide angular range and the world's smallest medical linac, offering potential improvements in treatment quality and equipment utilization. Position to procurement teams as a system upgrade with capex efficiency and reduced downtime compared with legacy platforms.

Revenue Growth Current revenue range and imminent regulatory clearance create opportunities to target capital budgets, leasing options, and payer-supported models. Prepare value-based case studies and total cost of ownership analyses to accelerate decisions in hospital finance committees.